Suda Pharmaceuticals Ltd (SUD) Is Yet to See Trading Action on Feb 15

February 15, 2018 - By Winifred Garcia

Shares of Suda Pharmaceuticals Ltd (ASX:SUD) closed at 0.014 yesterday. Suda Pharmaceuticals Ltd currently has a total float of 1.22 billion shares and on average sees 1.81M shares exchange hands each day. The stock now has a 52-week low of 0.013 and high of 0.028.

Why More Investors Are Looking Into S&P/ASX 200 Stocks

Australia takes pride with good corporate governance, which is why it is one of Asia’s fastest growing economies today. A nation’s good corporate governance improves its growth potentials as it lures domestic and foreign investors alike to bank on its equity market. CG Watch, which publishes ranks top Asian markets in terms of corporate governance biannually, has included Australia in its recent list.

The Australian Equity Market

Suda Pharmaceuticals Ltd is traded on the The Australian Securities Exchange (ASX) one of the biggest stock exchanges in Asia. And Suda Pharmaceuticals Ltd also included in its list. As of May 2014, over 2,000 companies are listed on the ASX, boasting with a total market capitalization of almost A$2 trillion.

One of the benchmark indices in Australia is the S&P/ASX 200, which tracks as much as 200 most actively traded stocks on the ASX.

The S&P/ASX 200

The S&P/ASX 200 carries on from All Ordinaries, which was formed in January 1980 to serve as the main Australian benchmark index, when it was established in April 2000. It had started at 3,133.30 points.

Continuing from the history of All Ordinaries, the S&P/ASX 200 had hit its all-time low of 1,358.50 points in November 1992. Eventually, it was able to recover, hitting its all-time high of 6,828.70 points during the same month in 2007. In February of that year, the S&P/ASX 200 had first reached the 6,000 mark. Investors had flocked the ASX that time, seeking for safe-haven assets in preparation for the Global Financial Crisis of 2008 amid early signs pointing out to its onslaught. Australia have always boasted with a compelling borrowing environment, which is why investors have always relied to its economy for valuable investment growth.

The S&P/ASX 200 is rebalanced quarterly by a panel of five members, the Index Committee. The review happens on the 16th of every quarter-end month— March, June, September, and December. Up to 200 companies make up the S&P/ASX, depending on their liquidity, market capitalization, and other factors. Suda Pharmaceuticals Ltd liquidity gives it an ability to perform the obligations with ease.

The S&P/ASX 200 is a free-float market-capitalization-weighted index, which means that stocks are evaluated based on their respective market capitalizations with respect to their share prices. Given this, stocks held by venture capitalists and the government are excluded since they are not often traded on the ASX.

When the components of the S&P/ASX 200 were last reviewed on September 16, six stocks had been removed while six new stocks had been included. Roughly 40% of the index is composed of the financial sector.

The S&P/ASX 200 represents about 80% of the total market valuation on the ASX, which is why it is an important indicator of the Australian economy. Similarly, it has a huge impact on the entire Asian economy.

Investors can surely benefit from the low interest rates and a healthy equity market in Australia. Suda Pharmaceuticals Ltd has relatively good liquidity. That being said, investing in ASX stocks is highly recommended for those who are seeking higher near-term and long-term returns alike. Investors prefer the companies like Suda Pharmaceuticals Ltd where they can easily see its liquidity ratio.

More news for Suda Pharmaceuticals Ltd (ASX:SUD) were recently published by:, which released: “NovaDel Announces Stockholder Approval of Sale of Substantially All Assets to …” on July 19, 2013.‘s article titled: “Global Pain Drug Development Pipeline Review Report 2017 Featuring 170+ …” and published on July 10, 2017 is yet another important article.

Suda Pharmaceuticals Ltd operates as a drug delivery firm that focuses on oro-mucosal administration in Australia. The company has market cap of $17.10 million. The Company’s product pipeline includes ZolpiMist, a US approved, oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia; ArTiMist, a sub-lingual spray for the treatment of p. falciparum severe paediatric malaria; SUD-001, an oral spray formulation that is used for the treatment of acute migraine in adults; and SUD-002, an oral spray formulation of ondansetron to treat nausea and vomiting induced by chemotherapy or radiotherapy, and other post-operative settings. It currently has negative earnings. The Company’s product pipeline also comprises SUD-003, an oral spray formulation of sildenafil sprayed directly in the mouth over the tongue for the treatment of erectile dysfunction; SUD-004, an oral spray formulation of sildenafil to treat pulmonary arterial hypertension in adults; and SUD-005, an oral spray formulation of midazolam for the treatment of pre-procedure anxiety in imaging and dental procedures, and also in the treatment of epileptic seizures.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: